Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study

Hidese, Shinsuke; Yoshida, Fuyuko; Ishida, Ikki; Matsuo, Junko; Hattori, Kotaro

doi:10.1002/npr2.12304

Cited by 11 publications

(12 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to CSS, we found a significant correlation between α-MSH and cognitive function in TRS. However, similar studies are scarce, and a recent study 54 has come to the opposite conclusion from our study. We currently have an understanding of the mechanisms underlying the role of α-MSH and the DA system in feeding behavior 98 , and other investigators have explored the role of α-MSH autoantibodies (autoAbs) in impaired cognitive function 99 .…”

Section: Discussioncontrasting

confidence: 99%

“…Consistent with the latest emerging study 54 , we found that the level of cognitive function in schizophrenic patients was not implicated in neuropeptide levels such as S.P and OT. In contrast, our research found that the levels of NT, BE and α-MSH were significantly correlated with cognitive function.…”

Section: Discussionsupporting

confidence: 90%

“…As predicted, levels of the five neuropeptides (α-MSH, BE, OT, NT and S.P) were significantly higher in chronic male SCZ patients than in healthy controls. However, these five neuropeptides have only recently been studied and previous results did not reveal significant differences between schizophrenic patients and HC 54 . Interestingly, there have also been studies showing significantly higher levels of BE in schizophrenic patients 55 , 56 , and others have concluded that low levels of OT are associated with SCZ 57 , 58 .…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia

Sun,

Jin,

Yang

et al. 2024

Schizophr

View full text Add to dashboard Cite

Serum neuropeptide levels may be linked to schizophrenia (SCZ) pathogenesis. This study aims to examine the relation between five serum neuropeptide levels and the cognition of patients with treatment-resistant schizophrenia (TRS), chronic stable schizophrenia (CSS), and in healthy controls (HC). Three groups were assessed: 29 TRS and 48 CSS patients who were hospitalized in regional psychiatric hospitals, and 53 HC. After the above participants were enrolled, we examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the blood serum levels of α-melanocyte stimulating hormone (α-MSH), β-endorphin (BE), neurotensin (NT), oxytocin (OT) and substance.P (S.P). Psychiatric symptoms in patients with SCZ were assessed with the Positive and Negative Syndrome Scale. SCZ patients performed worse than HC in total score and all subscales of the RBANS. The levels of the above five serum neuropeptides were significantly higher in SCZ than in HC. The levels of OT and S.P were significantly higher in CSS than in TRS patients. The α-MSH levels in TRS patients were significantly and negatively correlated with the language scores of RBANS. However, the BE and NT levels in CSS patients were significantly and positively correlated with the visuospatial/constructional scores of RBANS. Moreover, the interaction effect of NT and BE levels was positively associated with the visuospatial/constructional scores of RBANS. Therefore, abnormally increased serum neuropeptide levels may be associated with the physiology of SCZ, and may cause cognitive impairment and psychiatric symptoms, especially in patients with TRS.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia

Sun,

Jin,

Yang

et al. 2024

Schizophr

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there was only one study comparing the differences of the plasma neuropeptides between schizophrenia, BD and MDD subjects compared with controls (56). In Hidese et al's (56) study, the authors reported there was no difference of plasma α-MSH, β-endorphin, neurotensin, oxytocin, and substance P between patient groups and controls in a larger sample size. And they did not find any significant correlation between these above-mentioned plasma neuropeptides with clinical symptom and cognitive function.…”

Section: Discussionmentioning

confidence: 91%

Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function

Zhao

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundThere is an urgent need to identify differentiating and disease-monitoring biomarkers of schizophrenia, bipolar disorders (BD), and major depressive disorders (MDD) to improve treatment and management.MethodsWe recruited 54 first-episode schizophrenia (FES) patients, 52 BD patients, 35 MDD patients, and 54 healthy controls from inpatient and outpatient clinics. α-Melanocyte Stimulating Hormone (α-MSH), β-endorphin, neurotensin, orexin-A, oxytocin, and substance P were investigated using quantitative multiplex assay method. Psychotic symptoms were measured using the Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS), manic symptoms using the Young Mania Rating Scale (YMRS), and depressive symptoms using 17 item-Hamilton Depression Rating Scale (HAMD). We additionally measured cognitive function by using a battery of tests given to all participants.Resultsα-MSH, neurotensin, orexin-A, oxytocin, and substance P were decreased in the three patient groups compared with controls. Neurotensin outperformed all biomarkers in differentiating patient groups from controls. There were no significant differences for 6 neuropeptides in their ability to differentiate between the three patient groups. Higher neurotensin was associated with better executive function across the entire sample. Lower oxytocin and higher substance p were associated with more psychotic symptoms in FES and BD groups. β-endorphin was associated with early morning wakening symptom in all three patient groups.ConclusionOur research shows decreased circulating neuropeptides have the potential to differentiate severe mental illnesses from controls. These neuropeptides are promising treatment targets for improving clinical symptoms and cognitive function in FES, BD, and MDD.

show abstract

“…The question of the endogenous level of melanocortins in depression remains open due to the small number of studies on this topic. Some researchers indicate a reduced plasma level of α-MSH in MDD patients [ 300 ], other authors do not detect any differences in the plasma level of α-MSH between MDD patients and healthy controls [ 301 ]. There were no differences between depressed patients and healthy controls in α-MSH and ACTH levels in cerebrospinal fluid and plasma [ 302 ].…”

Section: The Effect Of Melanocortins On Depression-like and Anxious B...mentioning

confidence: 99%

The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs

Markov

Долотов

Гривенников

2023

IJMS

View full text Add to dashboard Cite

Major depression is one of the most prevalent mental disorders, causing significant human suffering and socioeconomic loss. Since conventional antidepressants are not sufficiently effective, there is an urgent need to develop new antidepressant medications. Despite marked advances in the neurobiology of depression, the etiology and pathophysiology of this disease remain poorly understood. Classical and newer hypotheses of depression suggest that an imbalance of brain monoamines, dysregulation of the hypothalamic-pituitary-adrenal axis (HPAA) and immune system, or impaired hippocampal neurogenesis and neurotrophic factors pathways are cause of depression. It is assumed that conventional antidepressants improve these closely related disturbances. The purpose of this review was to discuss the possibility of affecting these disturbances by targeting the melanocortin system, which includes adrenocorticotropic hormone-activated receptors and their peptide ligands (melanocortins). The melanocortin system is involved in the regulation of various processes in the brain and periphery. Melanocortins, including peripherally administered non-corticotropic agonists, regulate HPAA activity, exhibit anti-inflammatory effects, stimulate the levels of neurotrophic factors, and enhance hippocampal neurogenesis and neurotransmission. Therefore, endogenous melanocortins and their analogs are able to complexly affect the functioning of those body’s systems that are closely related to depression and the effects of antidepressants, thereby demonstrating a promising antidepressant potential.

show abstract

Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 11 publications

References 61 publications

Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia

Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia

Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function

The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs

Contact Info

Product

Resources

About